Dornier MedTech Epos Ultra
This article was originally published in The Gray Sheet
Australian study of 160 plantar fasciitis patients treated with the extracorporaeal shockwave therapy (ESWT) device finds "no evidence to support a beneficial effect on pain, function and quality of life" compared with placebo at six and 12 weeks. Published in the Sept. 18 Journal of the American Medical Association and conducted by Rachelle Buchbinder, Cabrini Hospital, Victoria, Australia, et al., the study included patients randomized to receive either 1,000 mJ/mm or a placebo dose of 6.0 mJ/mm through three weekly treatments. Both groups showed "significant" improvements in pain and ability, investigators noted. The indication was approved via PMA in January (1"The Gray Sheet" Feb. 4, 2002, p. 25)...
You may also be interested in...
Clinical trials will begin in February to support a supplemental PMA filing for Dornier MedTech's Epos Ultra extracorporeal shockwave therapy (ESWT) device to treat tendon inflammation
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.